Top

Published in:

01-03-2011

Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions

Authors: Gaetano M. De Ferrari, Peter J. Schwartz

Published in: Heart Failure Reviews | Issue 2/2011

Abstract

Vagus nerve stimulation was performed experimentally for the first time more than 150 years ago. In the 1980s and 1990s, vagus nerve stimulation was shown, both in the anesthetized and in the conscious animal, to exert marked antiarrhythmic effects, particularly during acute myocardial ischemia. There is a strong rationale for a beneficial effect of augmented vagal activity in the setting of chronic heart failure. Studies in experimental models of heart failure showed that chronic vagus nerve stimulation exerts beneficial effects on left ventricular function and on survival. Vagus nerve stimulation is approved in man for refractory epilepsy and depression. The first-in-man study performed in 32 patients with chronic heart failure suggests that vagus nerve stimulation was safe and well tolerated. Six months of open-label treatment was associated with significant improvements (P < 0.001) in NYHA class, quality of life, 6-min walk test, LV ejection fraction (from 22 ± 7 to 29 ± 8%), and LV systolic volumes (P = 0.02). These improvements were maintained at 1 year. Mechanisms of action may include the following: heart rate, anti-adrenergic, anti-apoptotic, and anti-inflammatory effects as well as an increase in nitric oxide. Controlled clinical trials will start soon to assess whether vagus nerve stimulation can indeed represent a new non-pharmacological approach for the treatment of symptomatic heart failure.

Einbrodt (1859) Ueber Herzreizung und ihr Verhaeltnis zum Blutdruck. Akademie der Wissenschaften (Vienna). Sitzungsberichte 38:345

Hering HE (1901) Die Myoerethischen Unregelmaessigkeiten des Herzens. Praeger Medizinische Wochenschrift 26:7

Scherf D (1929) Untersuchungen ueber die Entstehungweise der Extrasystolen und der extrasystolischen Allorhythmien. Z Exp Med 65:198CrossRef

Scherf D, Blumenfeld S, Yildiz M (1961) Experimental study on ventricular extrasystoles provoked by vagal stimulation. Am Heart J 62:670–675CrossRefPubMed

Garrey WE (1908) Some effects of cardiac nerves upon ventricular fibrillation. Am J Physiol 21:283–300

Shumacker HB Jr, Riberi A, Boone RD, Kajikuri H (1956) Ventricular fibrillation in the hypothermic state. IV. The role of extrinsic cardiac innervation. Ann Surg 143:223–229PubMed

Scherlag BJ, Helfant RH, Haft JI, Damato AN (1970) Electrophysiology underlying ventricular arrhythmias due to coronary ligation. Am J Physiol 219:1665–1671PubMed

Kerzner J, Wolf M, Kosowsky BD, Lown B (1973) Ventricular ectopic rhythms following vagal stimulation in dogs with acute myocardial infarction. Circulation 47:44–50PubMed

Kent KM, Smith ER, Redwood DR, Epstein SE (1973) Electrical stability of acutely ischemic myocardium: influences of heart rate and vagal stimulation. Circulation 47:291–298PubMed

10.

Goldstein RE, Karsh RB, Smith ER, Orlando M, Norman D, Farnham G, Redwood DR, Epstein SE (1973) Influence of atropine and of vagally mediated bradycardia on the occurrence of ventricular arrhythmias following acute coronary occlusion in closed-chest dogs. Circulation 47:1180–1190PubMed

11.

Myers RW, Pearlman AS, Hyman RM, Goldstein RA, Kent KM, Goldstein RE, Epstein SE (1974) Beneficial effects of vagal stimulation and bradycardia during experimental acute myocardial ischemia. Circulation 49:943–947PubMed

12.

Corr PB, Gillis RA (1974) Role of the vagus nerves in the cardiovascular changes induced by coronary occlusion. Circulation 49:86–97PubMed

13.

Yoon MS, Han J, Tse WW, Rogers R (1977) Effects of vagal stimulation, atropine, and propranolol on fibrillation threshold of normal and ischemic ventricles. Am Heart J 93:60–65CrossRefPubMed

14.

Yoon MS, Fondacaro JD, Han J (1978) Effects of vagal stimulation and atropine on ventricular arrhythmias during acute coronary occlusion. J Electrocardiol 11:27–31CrossRefPubMed

15.

Kolman BS, Verrier RL, Lown B (1975) The effect of vagus nerve stimulation upon vulnerability of the canine ventricle: Role of the sympathetic-parasympathetic interactions. Circulation 52:578–585PubMed

16.

Furey SA 3rd, Levy MN (1983) Interactions among heart rate, autonomic activity, and arterial pressure upon the multiple repetitive extrasystole threshold in the dog. Am Heart J 106:1112–1120CrossRefPubMed

17.

Murdock DK, Loeb JM, Euler DE, Randall WC (1980) Electrophysiology of coronary reperfusion. A mechanism for reperfusion arrhythmias. Circulation 61:175–182PubMed

18.

Zuanetti G, De Ferrari GM, Priori SG, Schwartz PJ (1987) Protective effect of vagal stimulation on reperfusion arrhythmias in cats. Circ Res 61:429–435PubMed

19.

Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1135CrossRefPubMed

20.

Schwartz PJ, Billman GE, Stone HL (1984) Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with a healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation 69:790–800PubMed

21.

De Ferrari GM, Vanoli E, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ (1991) Vagal reflexes and survival during acute myocardial ischemia in conscious dogs with a healed myocardial infarction. Am J Physiol 261:H63–H69PubMed

22.

Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ (1991) Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 68:1471–1481PubMed

23.

Schwartz PJ, Pagani M, Lombardi F, Malliani A, Brown AM (1973) A cardiocardiac sympathovagal reflex in the cat. Circ Res 32:215–220PubMed

24.

De Ferrari GM, Salvati P, Grossoni M, Ukmar G, Vaga L, Patrono C, Schwartz PJ (1993) Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. J Am Coll Cardiol 22:283–290CrossRefPubMed

25.

Ando M, Katare RG, Kakinuma Y, Zhang D, Yamasaki F, Muramoto K, Sato T (2005) Efferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by preserving connexin43 protein. Circulation 112:164–170CrossRefPubMed

26.

Schwartz PJ, De Ferrari GM (2010) Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev doi: 10.1007/s10741-010-9179-1. Online First™, 25 June 2010

27.

Waxman MB, Downar E, Berman ND, Felderhof CH (1974) Phenylephrine (Neo-synephrine) terminated ventricular tachycardia. Circulation 50:656–664PubMed

28.

Waxman MB, Wald RW (1977) Termination of ventricular tachycardia by an increase in cardiac vagal drive. Circulation 56:385–391PubMed

29.

Waxman MB, Cupps CL, Cameron DA (1988) Modulation of an idioventricular rhythm by vagal tone. J Am Coll Cardiol 11:1052–1060CrossRefPubMed

30.

Facchini M, De Ferrari GM, Bonazzi O, Weiss T, Schwartz PJ (1991) Effect of reflex vagal activation on frequency of ventricular premature complexes. Am J Cardiol 68:349–354CrossRefPubMed

31.

Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K (2004) Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109:120–124CrossRefPubMed

32.

Sabbah HN, Rastogi S, Mishra S, Gupta RC, Ilsar I, Imai M, Cohen U, Ben-David T, Ben-Ezra O (2005) Long-term therapy with neuroselective electric vagus nerve stimulation improves LV function and attenuates global LV remodelling in dogs with chronic heart failure. (abstr) Eur J Heart Fail (Suppl) 4:166

33.

Sabbah HN, Imai M, Zaretsky A, Rastogi, S, Wang M, Jiang A, Zaca V (2007) Therapy with vagus nerve electrical stimulation combined with beta-blockade improves left ventricular systolic function in dogs with heart failure beyond that seen with beta-blockade alone. (abstr) Eur J Heart Fail (Suppl 1) 6:114

34.

Zhang Y, Popovic ZB, Bibevski S, Fakhry I, Sica DA, Van Wagoner DR, Mazgalev TN (2009) Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2:692–699CrossRefPubMed

35.

Sabbah HN, Wang M, Jiang A, Ruble SB, Hamann JJ (2010) Right vagus nerve stimulation improves left ventricular function in dogs with heart failure. (abstr) J Am Coll Cardiol (Suppl) 55:A16.E151

36.

Ben-Menachem E (2001) Vagus nerve stimulation, side effects, and long-term safety. J Clin Neurophysiol 18:415–418CrossRefPubMed

37.

Schachter SC (2002) Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology 59:S15–S20PubMed

38.

Uthman BM, Reichl AM, Dean JC, Eisenschenk S, Gilmore R, Reid S, Roper SN, Wilder BJ (2004) Effectiveness of vagus nerve stimulation in epilepsy patients, a 12-year observation. Neurology 63:1124–1126PubMed

39.

Nemeroff CB, Mayberg HS, Krahl SE, McNamara J, Frazer A, Henry TR, George MS, Charney DS, Brannan SK (2006) VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 31:1345–1355CrossRefPubMed

40.

Shuchman M (2007) Approving the vagus-nerve stimulator for depression. N Engl J Med 356:1604–1607CrossRefPubMed

41.

Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A (2008) Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 10:884–891CrossRefPubMed

42.

De Ferrari GM, Crijns HJGM, Borggrefe M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Dennert R, Kuschyk J, Raspopovic S, Klein H, Swedberg K, Schwartz PJ (2010) Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. doi: 10.1093/eurheartj/ehq391

43.

De Ferrari GM, Vanoli E, Schwartz PJ (1994) Vagal activity and ventricular fibrillation. In: Levy MN, Schwartz PJ (eds) Vagal control of the heart: experimental basis and clinical implications. Futura Publishing Co, Armonk, NY, pp 613–636

44.

Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Cowell JW, Ross J Jr, Braunwald E (1971) Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43:67–82PubMed

45.

Lechat P, Hulot J-S, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H, on behalf of the CIBIS II Investigators (2001) Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103:1428–1433

46.

Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885

47.

Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS (2008) Parasympathetic nervous system and heart failure. Pathophysiology and potential implications for therapy. Circulation 118:863–871CrossRefPubMed

48.

Tracey KJ (2002) The inflammatory reflex. Nature 420:853–859CrossRefPubMed

49.

Borggrefe M, De Ferrari GM, Crijns HJ, Milasinovic G, Klein H, Zabel M, Gavazzi A, Kuschyk J, Schoene A, Sanzo A, Dennert R, Raspopovic S, Smid J, Iacovoni A, Schwartz PJ (2009) Chronic vagus nerve stimulation in patients with heart failure: potential predictors of success. (abstr) Circulation (Suppl) 120:S911

50.

Billman GE, Schwartz PJ, Stone HL (1984) The effects of daily exercise on susceptibility to sudden cardiac death. Circulation 69:1182–1189PubMed

51.

La Rovere MT, Bersano C, Gnemmi M, Specchia G, Schwartz PJ (2002) Exercise-induced increase in baroreflex sensitivity predicts improved prognosis after myocardial infarction. Circulation 106:945–949CrossRefPubMed

52.

De Ferrari GM, Mantica M, Vanoli E, Hull SS Jr, Schwartz PJ (1993) Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. J Am Coll Cardiol 22:1327–1334CrossRefPubMed

53.

La Rovere MT, De Ferrari GM (1995) New potential uses for transdermal scopolamine (hyoscine). Drugs 50:769–776CrossRefPubMed

54.

Desai MY, Watanabe M, Laddu A. Hauptman PJ (2010) Pharmacologic modulation of parasympathetic activity in heart failure. Heart Fail Rev

55.

Meerson FZ, Radzievskiǐ SA, Vorontsova E, Golubeva L, Chuvi’Iskaia LM (1989) Possibility of reflex activation of stress-limiting systems and the prevention of arrhythmia by electroacupuncture. Kardiologiia 29:88–90PubMed

56.

Zamotrinsky A, Afanasiev S, Karpov RS, Cherniavsky A (1997) Effects of electrostimulation of the vagus afferent endings in patients with coronary artery disease. Coron Artery Dis 8:551–557PubMed

57.

Zamotrinsky AV, Kondratiev B, de Jong JW (2001) Vagal neurostimulation in patients with coronary artery disease. Auton Neurosci 88:109–116CrossRefPubMed

58.

Schwartz SI, Griffith LS, Neistadt A, Hagfors N (1967) Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Sur 114:5–15CrossRef

59.

Braunwald E, Epstein SE, Glick G, Wechsler AS, Braunwald NS (1967) Relief of angina pectoris by electrical stimulation of the carotid sinus nerves. N Eng J Med 277:1278–1283CrossRef

60.

Tordoi JH, Schmidli SI, Savolainen H, Liebeskind U, Hansky B, Herold U, Irwin E, Kroon AA, de Leeuw P, Peters TK, Kieval R, Cody R (2007) An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg 33:414–421CrossRef

61.

Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS (2004) Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 43:306–311CrossRefPubMed

62.

Rheos hypertension system demonstrates feasibility; phase 3 trial under way. 30 March, 2009. http://www.theheart.org/article/954051.do. Accessed 10 May 2010

63.

Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FCGJ, Haller H, Pichlmaier AM, Luft FC, Jordan J (2010) Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55:619–626CrossRefPubMed

64.

Zucker IH, Hackley JF, Cornish KG, Hiser BA, Anderson NR, Kieval R, Irwin ED, Serdar DJ, Peuler JD, Rossing MA (2007) Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 50:904–910CrossRefPubMed

65.

Olgin JE, Takahashi T, Wilson E, Vereckei A, Steinberg H, Zipes DP (2002) Effects of thoracic spinal cord stimulation on cardiac autonomic regulation of the sinus and atrioventricular nodes. J Cardiovasc Electrophysiol 13:475–481CrossRefPubMed

66.

Lopshire JG, Zhou X, Dusa C, Ueyama T, Rosenberger J, Courtney N, Ujhelyi M, Mullen T, Das M, Zipes DP (2009) Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model. Circulation 120:286–294CrossRefPubMed

67.

Schauerte P, Mischke K, Plisiene J, Waldmann M, Zarse M, Stellbrink C, Schimpf T, Knackstedt C, Sinha A, Hanrath P (2001) Catheter stimulation of cardiac parasympathetic nerves in humans. A novel approach to the cardiac autonomic nervous system. Circulation 104:2430–2435CrossRefPubMed

68.

Bianchi S, Rossi O, Della Scala A, Kornet L, Pulvirenti R, Monari G, Di Renzi P, Schauerte P, Azzolinini P (2009) Atrioventricular (AV) node vagal stimulation by transvenous permanent lead implantation to modulate AV node function: safety and feasibility in humans. Heart Rhythm 6:1282–1286CrossRefPubMed

69.

Katare RG, Ando M, Kakinuma Y, Arikawa M, Handa T, Yamasaki F, Sato T (2009) Vagal nerve stimulation prevents reperfusion injury through inhibition of opening of mitochondrial permeability transition pore independent of the bradycardiac effect. J Thorac Cardiovasc Surg 137:223–231CrossRefPubMed

70.

Uemura K, Zheng C, Li M, Kawada T, Sugimachi M (2010) Early short-term vagal nerve stimulation attenuates cardiac remodeling after reperfused myocardial infarction. J Cardiac Fail 16:689–699CrossRef

71.

Ronson RS, Puskas JD, Thourani VH, Velez DA, Bufkin BL, Glass J, Guyton RA, Vinten-Johansen J (2003) Controlled intermittent asystole cardiac therapy induced by pharmacologically potentiated vagus nerve stimulation in normal and hibernating myocardium. Ann Thorac Surg 75:1929–1936CrossRefPubMed

72.

Robinson TG, Carr SJ (2002) Cardiovascular autonomic dysfunction in uremia. Kidney Int 62:1921–1932CrossRefPubMed

73.

Kuncová J, Šviglerová J, Kummer W, Rajdl D, Chottová-Dvořáková M, Tonar Z, Nalos L, Štengl M (2009) Parasympathetic regulation of heart rate in rats after 5/6 nephrectomy is impaired despite functionally intact cardiac innervation. Nephrol Dial Transplant 24:2362–2370CrossRefPubMed

Title: Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions
Authors: Gaetano M. De Ferrari
Peter J. Schwartz
Publication date: 01-03-2011
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2011
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-010-9216-0

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Methods of assessing vagus nerve activity and reflexes

Vagus nerve stimulation in experimental heart failure

Sympathetic–parasympathetic interaction in health and disease: abnormalities and relevance in heart failure

Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation

Pharmacologic modulation of parasympathetic activity in heart failure

Histopathology of the stimulated Vagus nerve: primum non nocere

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page